---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-017860"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:49:13.384550+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# MindMed Q1 net loss $24.8M, cash $129.4M; key trial readouts on track for late 2023

## Summary
- Net loss of $24.8M in Q1 2023 vs $18.5M in Q1 2022; R&D expenses rose to $12.6M (up $2.4M YoY).
- Cash and equivalents $129.4M at Mar 31, 2023; expected to fund operations into H1 2025.
- Phase 2b MM-120 for GAD and Phase 2a for ADHD both on track for topline results in late 2023.
- Appointed Mark R. Sullivan as Chief Legal Officer in April 2023.
- Plan to initiate Phase 1 trial of MM-402 for ASD in 2023; pre-clinical data at ASCP May 2023.

## SEC filing metadata
- accession: 0000950170-23-017860
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017023017860/0000950170-23-017860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017023017860/mnmd-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-017860
- JSON: https://secwatch.observer/filing/0000950170-23-017860.json
- Plain text: https://secwatch.observer/filing/0000950170-23-017860.txt

## Key facts
- Earnings Releases
  Definium Therapeutics, Inc. updated its the quarter ended March 31, 2023 guidance (reaffirmed).
  - Period: the quarter ended March 31, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1813814/000095017023017860/0000950170-23-017860-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.